WO2008152093A3 - Diaminopyrimidines as modulators of the ep2 receptor - Google Patents

Diaminopyrimidines as modulators of the ep2 receptor Download PDF

Info

Publication number
WO2008152093A3
WO2008152093A3 PCT/EP2008/057387 EP2008057387W WO2008152093A3 WO 2008152093 A3 WO2008152093 A3 WO 2008152093A3 EP 2008057387 W EP2008057387 W EP 2008057387W WO 2008152093 A3 WO2008152093 A3 WO 2008152093A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
diaminopyrimidines
modulators
inopyrimidines
diam
Prior art date
Application number
PCT/EP2008/057387
Other languages
French (fr)
Other versions
WO2008152093A2 (en
Inventor
Bernd Buchmann
Nico Braeuer
Marcus Koppitz
Olaf Peters
Laak Antonius Ter
Bernhard Lindenthal
Gernot Langer
Tim Wintermantel
Original Assignee
Bayer Schering Pharma Ag
Bernd Buchmann
Nico Braeuer
Marcus Koppitz
Olaf Peters
Laak Antonius Ter
Bernhard Lindenthal
Gernot Langer
Tim Wintermantel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag, Bernd Buchmann, Nico Braeuer, Marcus Koppitz, Olaf Peters, Laak Antonius Ter, Bernhard Lindenthal, Gernot Langer, Tim Wintermantel filed Critical Bayer Schering Pharma Ag
Publication of WO2008152093A2 publication Critical patent/WO2008152093A2/en
Publication of WO2008152093A3 publication Critical patent/WO2008152093A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to diam inopyrimidines of the general formula I, process for their preparation, and the use thereof for the manufacture of pharmaceutical compositions for the treatment of disorders and indications connected with the EP2 receptor.
PCT/EP2008/057387 2007-06-13 2008-06-12 Diaminopyrimidines as modulators of the ep2 receptor WO2008152093A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07075499A EP2014657A1 (en) 2007-06-21 2007-06-21 Diaminopyrimidines as modulators for an EP2 receptor
EP07075499.9 2007-06-21

Publications (2)

Publication Number Publication Date
WO2008152093A2 WO2008152093A2 (en) 2008-12-18
WO2008152093A3 true WO2008152093A3 (en) 2009-04-09

Family

ID=38663065

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/057387 WO2008152093A2 (en) 2007-06-13 2008-06-12 Diaminopyrimidines as modulators of the ep2 receptor

Country Status (3)

Country Link
US (1) US20090023738A1 (en)
EP (1) EP2014657A1 (en)
WO (1) WO2008152093A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7159215B2 (en) 2017-05-18 2022-10-24 イドーシア ファーマシューティカルズ リミテッド Pyrimidine derivatives as PGE2 receptor modulators
JP7159214B2 (en) 2017-05-18 2022-10-24 イドーシア ファーマシューティカルズ リミテッド Phenyl derivatives as PGE2 receptor modulators
JP7253500B2 (en) 2017-05-18 2023-04-06 イドーシア ファーマシューティカルズ リミテッド pyrimidine derivative

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0719644D0 (en) * 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP5600063B2 (en) 2007-10-19 2014-10-01 セルジーン アビロミクス リサーチ， インコーポレイテッド Heteroaryl compounds and uses thereof
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
WO2011088027A1 (en) * 2010-01-13 2011-07-21 Glaxosmithkline Llc Compounds and methods
JP2013526513A (en) * 2010-05-11 2013-06-24 クリサニ バイオサイエンシーズ プライベート リミッテッド 4,6-Dibenzylamine-2-methyl-pyrimidine derivatives and their use for cancer treatment
CA2798578C (en) 2010-05-21 2015-12-29 Chemilia Ab Novel pyrimidine derivatives
US9006241B2 (en) 2011-03-24 2015-04-14 Noviga Research Ab Pyrimidine derivatives
EP2711364A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
EP2711365A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
HRP20220522T1 (en) * 2014-08-04 2022-06-10 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
CR20180323A (en) * 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd DERIVATIVES OF INDOL N-SUBSTITUTES AS MODULATORS OF PGE2 RECEIVERS
US10590084B2 (en) 2016-03-09 2020-03-17 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
AU2017292646A1 (en) 2016-07-05 2019-02-07 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
SG10201912574WA (en) 2016-09-28 2020-02-27 Blade Therapeutics Inc Calpain modulators and therapeutic uses thereof
EP3625224B1 (en) * 2017-05-18 2021-08-04 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
MX2022007265A (en) 2019-12-20 2022-09-09 Nuevolution As Compounds active towards nuclear receptors.
MX2022012260A (en) 2020-03-31 2022-11-30 Nuevolution As Compounds active towards nuclear receptors.
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors
CN112574192B (en) * 2020-12-24 2021-10-01 烟台大学 Amino acid derivative bithiazole-tryptamine anticancer compound and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050256170A1 (en) * 2004-02-12 2005-11-17 Oxford Alexander W EP2 receptor agonists
WO2006044732A2 (en) * 2004-10-15 2006-04-27 Aventis Pharmaceuticals Inc. 2, 6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050256170A1 (en) * 2004-02-12 2005-11-17 Oxford Alexander W EP2 receptor agonists
WO2006044732A2 (en) * 2004-10-15 2006-04-27 Aventis Pharmaceuticals Inc. 2, 6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7159215B2 (en) 2017-05-18 2022-10-24 イドーシア ファーマシューティカルズ リミテッド Pyrimidine derivatives as PGE2 receptor modulators
JP7159214B2 (en) 2017-05-18 2022-10-24 イドーシア ファーマシューティカルズ リミテッド Phenyl derivatives as PGE2 receptor modulators
JP7253500B2 (en) 2017-05-18 2023-04-06 イドーシア ファーマシューティカルズ リミテッド pyrimidine derivative

Also Published As

Publication number Publication date
WO2008152093A2 (en) 2008-12-18
EP2014657A1 (en) 2009-01-14
US20090023738A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
WO2008152093A3 (en) Diaminopyrimidines as modulators of the ep2 receptor
WO2008152099A3 (en) Aryl/hetarylamides as modulators of the ep2 receptor
WO2012009009A3 (en) Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
WO2009069032A3 (en) Novel glucocorticoid receptor agonists
WO2008097428A3 (en) Compounds and compositions as modulators of gpr119 activity
WO2008132139A3 (en) New heterocyclic derivatives useful for the treatment of cns disorders
WO2011007230A3 (en) Lupeol-type triterpene derivatives as antivirals
MX2009006540A (en) Indazolyl ester and amide derivatives for the treatment of glucocorticoid receptor mediated disorders.
WO2010008831A3 (en) Compounds and methods for modulating g protein-coupled receptors
WO2010123930A3 (en) Chemosensory receptor ligand-based therapies
WO2007089557A3 (en) Polycyclic 1, 2, 3, 4 -tetrahydro- isoquinoline derivatives and compositions comprising them as ppar modulators
MY151246A (en) Benzofuranyl derivatives
GEP20135793B (en) Heteroaryls amide derivatives and their use as glucokinase activators
MY148948A (en) Catecholamine derivatives and prodrugs thereof
MX342257B (en) Oxaspiro [2.5] octane derivatives and analogs.
WO2010055082A3 (en) New crystal form of sunitinib malate
JO2645B1 (en) Compounds
TW200942535A (en) Novel compounds as cannabinoid receptor ligands
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
GB0611907D0 (en) Compounds
WO2009115084A3 (en) Pyrrolopyrimidine derivatives, and use thereof
WO2010049449A3 (en) Novel salts of sunitinib
WO2011023367A3 (en) Bisphosphonate-prodrugs
WO2011061744A3 (en) Novel arylated camphenes, processes for their preparation and uses thereof
MX2011012669A (en) Novel glucocorticoid receptor agonists.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08774075

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08774075

Country of ref document: EP

Kind code of ref document: A2